Written question asked by Earl Howe (Conservative), in the House of Lords. It was due for an answer on Monday, 9 February 2004. It was answered by Lord Warner (Labour) on Monday, 9 February 2004.
Warner, Lord
- Question
- Whether the research currently being conducted by the Moyne Institute of Preventive Medicine in Dublin into developing a vaccine to combat measles, mumps and rubella relying on recombinant ribonucleic acid instead of live viruses holds out the prospect of fewer adverse reactions; and whether they will monitor the results of this research [HL 1018].
Secondary information
- Type
- Written question
- Reference
- HL 1018; 657 c131WA
- Session
- 2003-04
- Subjects
- Genetic engineering Rubella Monitoring Safety Research Vaccination Side effects Viral diseases Measles Mumps
Librarians' tools
- Timestamp
- 2014-05-15 12:30:49 +0100
- URI
- http://data.parliament.uk/pimsdata/Hansard/PARLIAMENTARY_QUESTION_890930
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/pimsdata/Hansard/PARLIAMENTARY_QUESTION_890930
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/pimsdata/Hansard/PARLIAMENTARY_QUESTION_890930